Engineering the RRM2 subunit of ribonucleotide reductase to resist degradation
US12208133B2 · kind B2 · utility
0Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2019 |
| Grant date | Jan 28, 2025 |
| Priority date | — |
| Expiry date | Jul 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y117/04001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.